Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Clinical trial NCT02186821 · TERMINATED
Trial details
- NCT number
- NCT02186821
- Sponsor
- Novartis Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-17
- Primary completion
- 2017-12-13
- Enrollment
- 47
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.